Cavutilide (fixed dose) versus amiodarone in paroxysmal atrial fibrillation

Aim. The purpose of this study is to compare the single use of a fixed minimum dose of cavutilid (refralon; Russian Federation, E.I. Chazov National Medical Cardiology Research Centre) 350 μg with amiodarone in patients with paroxysms of atrial fibrillation and flutter.

Materials and methods. The study included 62 patients with paroxysmal atrial fibrillation and flutter, divided into two groups (31 patients each). The first group received single fixed dose of cavutilid 350 μg, the second — amiodarone at a starting dose of 5 mg / kg with a possible continuation of the infusion up to 1200 mg in case of failure to achieve sinus rhythm recovery. The patients did not differ in main clinical and instrumental parameters, except for the higher weight and duration of medical history in the amiodarone group. The effectiveness of cardioversion (restoration of sinus rhythm within 1 and 24 hours, time to restoration of sinus rhythm, reduction of heart rate, achievement of " lenient " heart rate control, absence of sustained relapses) and safety (presence of serious cardiovascular complications, ventricular arrhythmias, prolongation of QT/QTc intervals, severe bradycardia and pauses >3,0 sec, arterial hypotension).

Results. In the cavutilid group, sinus rhythm restoration within 1 hour was achieved in 87.1% of patients, in the amiodarone group — in 19.4% (p<0.001). After 24 hours, sinus rhythm was registered in 93.3% and 64.5%, respectively (p=0.011). Time to sinus rhythm restoration was significantly faster in patients of the cavutilid group (median 8.00 [5.00; 13.00] minutes versus 140.00 [60.75; 240.00] minutes for amiodarone; p<0.001). The arrhythmia recurrence rate, heart rate reduction, and achievement of "linient" frequency control did not differ statistically between the groups compared. Major adverse cardiovascular events and ventricular tachycardia were not reported in any of the groups. Prolongation of the QT/QTc interval was less common (in 2 patients, 6.5%, versus 5 patients, 16,1%; p=0,425) and lasted significantly less time after the use of cavutilid. Arterial hypotension was observed in 2 patients (6.5%) only in the amiodarone group.

Discussion. The high efficacy and safety of a single fixed dose of cavutilid 350 μg for pharmacological cardioversion of atrial fibrillation and flutter paroxysms demonstrate low risk of arrhythmogenic effects of the drug and the possibility of reducing patient follow-up time both in intensive care units and in general inpatient setting. Taking these advantages into consideration, we may suggest that fixed dose of cavutilid 350 μg has potential for outpatient use.

1. Samorodskaya I.V., Starinskaya M.A., Boytsov S.A. Changes of regional mortality rates from cardiovascular diseases and cognitive disorders in Russia over 2019-2021. Russian Journal of Cardiology. 2023;28(4):5256. (In Russ.) https://doi.org/10.15829/1560-4071-2023-5256]

2. Shapkina M.Yu., Mazdorova E.V., Avdeeva E.M., Shcherbakova L.V., Ryabikov A.N., Hubachek J.A., Bobak M., Malyutina S.K. Changes in the prevalence of atrial fibrillation in the Russian population over a 13-year follow-up. Cardiovascular Therapy and Prevention. 2022;21(8):3108. (In Russ.) https://doi.org/10.15829/1728-88002022-3108]

3. Kolbin A.S., Mosikyan A.A., Tatarsky B.A. Socioeconomic burden of atrial fibrillations in Russia: seven-year trends (2010-2017). Journal of Arrhythmology. 2018;(92):42-48. (In Russ.)]

4. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol. 2003 Jun;89(2-3):239-48. PMID: 12767548. https://doi.org/10.1016/s0167-5273(02)004771

5. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol. 1991 Nov;31(11):1061-9. PMID: 1753010. https://doi.org/10.1002/j.1552-4604.1991.tb03673.x

6. Latini, R., Tognoni, G. & Kates, R.E. Clinical Pharmacokinetics of Amiodarone. Clin Pharmacokinet. 1984;9:136-156 (1984). https:// doi.org/10.2165/00003088-198409020-00002

7. Trohman RG, Sharma PS, McAninch EA, Bianco AC. Amiodarone and thyroid physiology, pathophysiology, diagnosis and management. Trends Cardiovasc Med. 2019 Jul;29(5):285-295. Epub 2018 Sep 20. PMID: 30309693; PMCID: PMC6661016. https://doi.org/10.1016/j.tcm.2018.09.005

8. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997 Sep;30(3):791-8. PMID: 9283542. https://doi.org/10.1016/s0735-1097(97)00220-9

9. Mironov N.Yu., Vlodzyanovskiy V.V., Yuricheva Yu.A., Sokolov S.F., Golitsyn S.P., Rosenstraukh L.V., Chazov E.I. Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part I: Study Rationale, Design and Assessment of Effectiveness. Rational Pharmacotherapy in Cardiology. 2018;14(5):664-669. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-5-664-669]

10. Gagloeva D.A., Dzaurova Kh.M., Zelberg M.A., Mironov N.Yu., Yuricheva Yu.A., Sokolov S.F., Krymukova M.A., Salpagarova A.I., Dulaev L.O., Pevzner D.V., Golitsyn S.P. Preliminary results of a prospective randomized study comparing the efficacy and safety of refralon and amiodarone in cardioversion in patients with paroxysmal atrial fibrillation and flutter. Cardiovascular Therapy and Prevention. 2023;22(4):3527. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3527]

11. Mironov N.Yu., Vlodzyanovskiy V.V., Yuricheva Yu.A., Sokolov S.F., Golitsyn S.P., Rosenstraukh L.V., Chazov E.I. Safety and Effectiveness of Electrical and Pharmacological Cardioversion in Persistent Atrial Fibrillation. Part 2: Assessment of Safety. Rational Pharmacotherapy in Cardiology. 2018;14(6):826-830. https://doi.org/10.20996/1819-6446-2018-14-6-826-830]

12. Dzaurova KM, Mironov NY, Yuricheva YA, Vlodzyanovsky VV, Mironova NA, Laiovich LY, Malkina TA, Zinchenko LV, Sokolov SF, Golitsyn SP. [Efficiency and safety of using the modified protocol for the administration of the domestic class III antiarrhythmic drug for the relief of paroxysmal atrial fibrillation]. Ter Arkh. 2021 Sep 15;93(9):1052-1057. Russian. PMID: 36286864. https://doi.org/10.26442/00403660.2021.09.201008]

13. Chevalier, P, Durand-Dubief, A, Burri, H. et al. Amiodarone versus placebo and class ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. JACC. 2003 Jan;41(2):255-262. https://doi.org/10.1016/S0735-1097(02)02705-5